繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-810 (SAFETYNADOL)

SNP-810 (SAFETYNADOL)

Indication
Hepatotoxicity-free Acetaminophen (Analgesic and antipyretic)
Product Advantages
1. Hepatotoxicity-free
2. To address the important and urgent unmet medical needs
3. A patented formulation with great safety margin
Status
Phase I low-dose, high-dose completed (Pivotal trial applying for USFDA NDA)
Competitive Edge
1. Currently, no hepatotoxicity-free acetaminophen on the market
2. Great impact on the market share of pain controllers, especially to NSAIDS, Cox2 inhibitors and opioids
3. Reduction of lawsuit and compensation
Potential Market
Acetaminophen sales are 1.3 billion USD a year (US only)

Mechanism of Action of SNP-810 and NAC


好玩棋牌 山西福彩十一选五开奖结果 江苏快3开奖结果今天开奖号码查询结果 佳永股票配资_佳永配资平台|老牌配资公司 北京快车pk10app 贵州快三开奖结果查询今天500 大智慧手机炒股7.62 上海快3一定牛定牛上海 今日上证指数是多少 -点 百度 10月5日体彩排列3 北京拾赛车开奖结果